Ferrlecit is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older undergoing chronic hemodialysis (HD) who are receiving supplemental epoetin therapy.

Important Safety Information

• Ferrlecit is contraindicated in non iron-deficient anemias, in patients hypersensitive to Ferrlecit or its inactive components, or with evidence of iron overload
• Hypersensitivity reactions have been reported with injectable iron products
• Hypotension has been reported with rapid administration of IV iron
• In multiple-dose studies in adult patients, the most frequent adverse reactions (occurring at ≥ 10%) whether or not related to Ferrlecit administration were nausea, vomiting and/or diarrhea, injection site reaction, hypotension, cramps, hypertension, dizziness, abnormal erythrocytes, dyspnea, chest pain, leg cramps, and pain
• In a clinical trial in iron-deficient hemodialysis pediatric patients, the most common adverse reactions (occurring at ≥ 10%) whether or not related to Ferrlecit administration were hypotension, headache, hypertension, tachycardia, and vomiting

For more information, please see full Prescribing Information

Click here for information on drug anti-counterfeiting.